Summit Therapeutics Inc.
corporate_fare Company Profile
Summit Therapeutics Inc. (NASDAQ:SMMT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 47 items for SMMT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-25, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for SMMT spans DEF 14A, PRE 14A, 8-K, 10-Q.
Recent high-impact activity:
- Ivonescimab Beats Durvalumab in Biliary Tract Cancer: OS 14.9 vs 12.1 Months
- Summit Seeks 2B Authorized Shares to Cover AstraZeneca Conversion; Vote Nov 4
- Summit Seeks Shareholder Approval to Double Authorized Shares for AstraZeneca Conversion
- Summit Partners with AstraZeneca and Daiichi Sankyo on Ivonescimab-Datroway Combo
- AstraZeneca Invests $2B in Summit Therapeutics at $18.36/Share Premium
Financial Snapshot
Short Interest & Short Volume
7.02 days to coverFINRA reported short interest of 40,896,653 shares in SMMT as of the October 15, 2026 settlement, a 0.6% decrease from the prior period — about 7.0 days to cover at its recent average daily volume. On October 30, 2026, 49.0% of SMMT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for SMMT, detected from its recent SEC filings · based on capital-structure filings through 2026-09-29.
ATM Program Formalized · Dilution Details
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →